ReviewFrontiers in oncology2018

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

Ajaz Bulbul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.